How would you communicate a variant result that is technically solid but clinically uncertain?

Why

Analytical validity and clinical significance are different claims. Analytical validity asks whether the variant is really in the sample: depth, allele fraction, base and mapping quality, strand balance and, where needed, orthogonal confirmation. Clinical significance asks whether the variant causes disease.

The ACMG and AMP standards by Richards and colleagues use five terms: pathogenic, likely pathogenic, uncertain significance, likely benign and benign. They define likely as greater than 90 percent certainty, and they state that a variant of uncertain significance should not be used in clinical decision-making. The report should also describe the assay's methods and limitations, so a clinician can judge whether more testing is needed.

A clear write-up might say: the variant is detected with high confidence, and current evidence is insufficient to call it pathogenic or benign. Then list what could change the class, such as segregation in the family, functional data or population frequency. Avoid softening phrases such as possibly pathogenic, which are not in the scheme and invite misreading.

Classification can change as evidence accumulates, so the report should say reclassification is possible.